OncoMatch/Clinical Trials/NCT07689851
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Is NCT07689851 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies multiple treatments including SHR-1701 and COPOX for gastric cancer (gc).
Treatment: COPOX · SHR-1701 — Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis. This study aims to evaluate the safety and efficacy of radiotherapy combined with CAPOX and SHR-1701, a PD-L1/TGF-β bispecific antibody, in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. By improving local tumor control and enhancing systemic antitumor activity, this study seeks to increase the opportunity for curative-intent resection and improve survival outcomes in patients with advance gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: surgery for gastric or gastroesophageal junction cancer
No prior surgery ... for gastric or gastroesophageal junction cancer since diagnosis
Cannot have received: chemotherapy for gastric or gastroesophageal junction cancer
No prior ... chemotherapy ... for gastric or gastroesophageal junction cancer since diagnosis
Cannot have received: immunotherapy for gastric or gastroesophageal junction cancer
No prior ... immunotherapy ... for gastric or gastroesophageal junction cancer since diagnosis
Cannot have received: other antitumor therapy for gastric or gastroesophageal junction cancer
No prior ... other antitumor therapy for gastric or gastroesophageal junction cancer since diagnosis
Cannot have received: radiotherapy to the intended irradiation sites
No previous radiotherapy to the intended irradiation sites
Cannot have received: PD-1 inhibitor
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies
Cannot have received: PD-L1 inhibitor
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies
Cannot have received: TGF-β inhibitor
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies
Cannot have received: CTLA-4 inhibitor
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies
Cannot have received: investigational immunotherapy
Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies
Lab requirements
Blood counts
Hemoglobin ≥90 g/L; White blood cell count ≥3.5 × 10⁹/L; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L
Kidney function
Serum creatinine ≤1.0 × ULN; Blood urea nitrogen (BUN) ≤1.0 × ULN
Liver function
ALT ≤1.5 × ULN; AST ≤1.5 × ULN; ALP ≤1.5 × ULN; Total bilirubin (TBIL) ≤1.5 × ULN
Adequate organ function, including: Hemoglobin ≥90 g/L; White blood cell count ≥3.5 × 10⁹/L; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L; Serum creatinine ≤1.0 × ULN; Blood urea nitrogen (BUN) ≤1.0 × ULN; Alanine aminotransferase (ALT) ≤1.5 × ULN; Aspartate aminotransferase (AST) ≤1.5 × ULN; Alkaline phosphatase (ALP) ≤1.5 × ULN; Total bilirubin (TBIL) ≤1.5 × ULN; Negative urine protein; Normal coagulation function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07689851 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages